

Familial risks in prostate cancer between brothers and half-brothers as clues to germline genetic and environmental causes.

Kari Hemminki ^{1,2}, Frantisek Zitricky ¹, Kristina Sundquist ^{3,4,5}, Jan Sundquist ^{3,4,5}, Asta Försti ^{6,7}, Akseli Hemminki ^{8,9}, Otto Hemminki ^{9,10}

¹ Biomedical Center, Faculty of Medicine, Charles University, 30605 Pilsen, Czech Republic;

² Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Im Neuenheimer Feld 580, D-69120, Heidelberg, Germany;

³ Center for Primary Health Care Research, Lund University, 205 02 Malmö, Sweden;

⁴ University Clinic Primary Care Skåne, Region Skåne, Sweden;

⁵ Department of Family and Community Medicine, McGovern Medical School, The University of Texas Health Science Center, Houston, Texas, USA;

⁶ Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany;

⁷ Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany;

⁸ Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

⁹ Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland;

¹⁰ Department of Urology, Helsinki University Hospital, Helsinki, Finland

Correspondence to:

Kari Hemminki, Biomedical Center, Faculty of Medicine, Charles University, 30605 Pilsen, Czech Republic.

Email: k.hemminki@dkfz.de

Words: 3263 (text), 244 (abstract).

Key words: familial risk, germline genetics, heredity, half-brother, age of onset.

ABBREVIATIONS

BC breast cancer

FDR first-degree relative

CRC colorectal cancer

HB half-brother

PC prostate cancer

PRS polygenic risk score

PSA prostate specific antigen

RR relative risk

ABSTRACT

Swedish family and cancer data constitute the largest source on familial cancer in the world. We analyze here familial risks in prostate cancer (PC) with focus on multiple affected brothers and comparison of full-brothers to maternal and paternal half-brothers. Age-specific incidence and standardized incidence ratios (SIRs) were calculated for PC in brothers. Curves for relative risk (RR) by diagnostic age were plotted for risk distributions. A total of 115,066 PCs were diagnosed in 1.2 million men. Familial SIR for full brothers was 2.23, for maternal half-brothers it was 1.92 and paternal half-brothers was 1.34. Considering SIRs with least possible detection bias (7+ years after first brother's diagnosis) the above SIRs were 2.06, 1.66 and 1.41. SIRs in full brothers increased stepwise by the number of affected brothers reaching 21.33 when 6 brothers were affected. Age-RR curves for two affected brothers declined evenly from RR 2.8 at age 45 to below 2.0 at age 80. When four or more brothers were affected, a discrete high-risk peak (RR 4 to 7) was detected between ages 60 and 69. Data on full-brothers and half-brothers indicate that familial risk in PC is largely genetic which is also supported by discrete RR peaks in high-risk families at ages matching preferential penetrance age for known predisposition genes of PC. Familial risk increased already when two brothers were affected calling for clinical vigilance concerning family history. Family history should deserve a place as an inclusion criterium in schemes for PC screening.

INTRODUCTION

Familial clustering of cancer was initially observed for rare cancers in families with many affected individuals, later recognized as retinoblastoma and Li-Fraumeni syndromes (1). However, familial cancer gained a wider population-level impact through the collection of colorectal cancer families in the 1960s and 1970s by Henry Lynch, leading to the detection of the mismatch repair gene mutations as the underlying cause (2, 3). Parallely, gene finding efforts in breast cancer families led to the identification of the genes *BRCA1* and *BRCA2* (1). These discoveries boosted efforts for identification of novel cancer predisposition genes in families with an apparent clustering of certain cancers (linkage studies) and many new genes were discovered until about year 2002 (1). For prostate cancer (PC), linkage studies have not been helpful and for the current PC predisposition genes (*BRCA2*, *HOXB13*, *BRCA1*, *CHEK2*, *PALB2*, *ATM2* and mismatch repair genes) the verification has been done in case-control studies between large numbers of patients whose germline DNA has been sequenced (4-6). Combined pathogenic germline variants in the above genes may account, according to a review, for 3 to 5% of localized PC, 7% of familial PC and 12% of metastatic PC (7). The increasing variant proportion towards familial and metastatic patients suggests that such cases are enriched in variants with an

aggressive phenotype (6, 8-10). In Scandinavia, PC patients frequently harbor *HOXB13* mutations which were not included in the studies reviewed above (7, 9, 11).

In addition to the above genes, low-penetrance variants contribute to familial risk of PC, and risks combined for 100 or more loci may be calculated as the polygenic risk score (PRS) (12-14). Familial clustering and PRS are correlated, but independent; principally the genes/variants contributing to familial risk and PRS differ by the frequency of variants in the population (higher for PRS) and effect size (higher for predisposition genes)(15). The risks between these two types of variants are additive and may include also life-style risk factors (16). In general, the distinction between genetic and environmental effects may be difficult in a familial setting, and e.g., familial risk between spouses (correlation of cancer risk between spouses) has been one way to estimate environmental effects (17). Another powerful option is to compare cancer risk between full - and half-siblings for whom data are uniquely available in Sweden (18).

We apply here the nationwide updated family data of Sweden covering essentially a century with cancers from 1958 recorded in the national high-quality cancer registry (19). The special feature of the family data is their completeness for 16 million individuals, also including half-siblings have been recorded after parental divorce. In Sweden, children normally remained with the mother until about 1990 when joint custody of children became more common (20). The earlier versions of the dataset have been used in several family studies on PC (21-24). Using this resource we focus on age-specific analysis of familial PC between brothers (i.e., a single generation) based on the number of affected brothers, which should be informative of the penetrance age of high-risk germline variants for PC. Familial risk between brothers was selected because the difference in their diagnostic ages was smaller than between fathers and sons, which was considered important in view of the changing epidemiology of PC (fathers were diagnosed largely before the prostate specific antigen (PSA) era starting at around 1990 (25)). The main focus is on full-brothers (also ‘brothers’) and half-brothers. In further analyses, family members with selected discordant cancers of the breast and colorectal were included in attempts to delineate genetic effects by genes shared by PC and these other cancers. Previously we have shown the usefulness of the approach on various cancers without specifying family history (26, 27). Any reliable risk factors for PC are urgently needed because of the controversies about ongoing and planned screening practices (28).

METHODS

The analyzed dataset originates from the latest update of the Swedish Cancer Registry (covering period 1961- 2021), linked with the Multigeneration Register, which includes the Swedish population: generation 1 born before 1932 (median birth year 1912), generation 2 born in Sweden from 1932 onwards (median birth year 1947) and generation 3 children of parents from generation 2 (median birth year 1976). The present study focused on men in generation 2, except that breast and colorectal cancers were obtained for all first-degree relatives (FDRs). The oldest

persons in generation 2 reached age 89 years by 2021. Persons born after 1932 with missing links to parents were excluded. Half-brothers were available in the database, for maternal ones with the same biological mother and different father; for paternal ones, with the same biological father and different mother (18). All family and cancer linkages were done through the unique personal identification number. Cancers at specific sites were diagnosed through the ICD-7 codes for PC (177), breast cancer (BC, 170) and colorectal cancer (CRC, 153 and 154).

Incidence rates were calculated in 5-year age-brackets for incident cases in a defined age-group divided by person-years at risk in the same age-group. Cases were the sets of brothers who were diagnosed with PC. Reference rates were calculated for men without FDR diagnosed with PC. Rate ratios (RRs) were calculated by dividing the case incidence rate by the reference incidence rate, and the age-RR curves are shown with the incidence curves. Age-specific incidence and RRs were also developed for brothers diagnosed with PC when family members were diagnosed with discordant cancers of the breast and colorectum. The incidence rates were also calculated for specified time interval with respect to sibling's diagnosis date. The incidence rates for first diagnosed brother were calculated by considering that he and any of his brothers were at risk only until his (first brother's) diagnosis date.

In analysis of familial relative risk, one person of each family in generation 2 was defined as case and his full brothers or half-brothers diagnosed with PC were defined as probands. The calculation was based on the standardized incidence ratio (SIR) as the ratio of the observed number of PCs in population at risk to the expected number of PCs, i.e., cases whose FDR and half-brothers were not diagnosed with PC. The follow-up started on date of birth or beginning of the study (1st January 1961), whichever came later. The follow-up was terminated at time of death, emigration, PC diagnosis or end of study (29th December 2021), whichever came earliest. In SIR estimation with respect to brother's diagnostic date (Fig. 1 and SIR for first brother with PC in Table 1), the follow-up was further restricted to the defined time period. The rates were standardized based on sex, age (5-year groups), calendar period (10-year groups), educational level (<9 years, 9 years, 10-11 years, 12 years, college <3 years, university graduate, postgraduate) and geographic region (north, south and 3 largest cities). The 95% confidence intervals (CIs) were calculated assuming that observed rates follow Poisson distribution.

Throughout the manuscript, groups with estimated SIRs were labeled by total number of PC patients that would result if the followed person (case) was diagnosed with PC. Therefore, "2 brothers with PC" designates risk estimates for men with one brother proband diagnosed with PC.

All statistical analyses and data visualization were done using SAS and R (version 4.4.0).

Data on penetrance age for predisposition genes are presented in **Supplementary Table 1**.

RESULTS

Number of men in generation 2 (1,171,247), number with diagnosed PCs (115,070; 9.5%). Families with a single PC in generation 2 accounted for 83.2% of all, those with families of 2, 3 and 4 and more PCs accounted for 14.2, 2.1 and 0.5%, respectively

Familial risks for full and half-brothers

Case numbers and SIRs are shown in **Table 1**, separately considering risks for PC in all brothers in families with multiple brothers or in such families for the first diagnosed brother only. The reason for the two types of analyses was that the diagnosis in the first brother would not be biased by diagnosis in other brothers. In the case of half-brothers there was no difference between the SIRs. In column ‘risk to any brother’ SIR for paternal half-brothers was 1.34 and that for maternal half-brothers was 1.92 with a significant difference. SIR for full brothers was 2.23, significantly higher than that for either half-brothers.

Comparing SIRs for full brothers we can note that risk increases according to the number of affected brothers (**Table 1**). SIR reached 21.33 for 6 affected brothers (column ‘risk to any brother’) but only 16.78 when risk to the first brother was considered. The difference in SIRs between two columns increased by the number of affected brothers.

According to literature there is diagnostics bias for PC between brothers and the diagnosis of the first brother may cause concern and medical contacts in unaffected brothers (29, 30). We thus determined familial risks for brothers at various time intervals since diagnosis of the first brother (**Fig. 1**). Full brothers diagnosed within a year showed the highest SIR of 3.4, and a steeply decreasing risk reaching 2.0 in >10 years. For maternal half-brothers the peak SIR of 2.7 was reached at 2-3 years, followed by a decline to 1.7. For paternal half-brothers a modest increase in risk to 1.6 was noted at 7-10 years. The median difference in diagnostic time between the first and the second brother was 58 months for FBs, 55 months for maternal half-brothers and 74 months for paternal half-brothers.

According to **Fig. 1** it seemed that the risks between brothers stabilized with extended time difference between the diagnoses of the brother pairs. Considering also case numbers were selected the period past 7 years of diagnosis for the least biased comparison. The SIR after 7+ years for full-brothers was 2.06 (N 3423, 95%CI 1.99-2.13); for maternal half-brothers it was 1.66 (N 77, 95%CI 1.31-2.08) and for paternal half-brothers it was 1.41 (N 82, 95%CI 1.12-1.74).

Familial age-specific risks for PC

Age-specific RRs for PC in the first diagnosed brother depending on the number of affected brothers (irrespectively of PC in other first-degree relatives) are shown in **Fig. 2** (solid lines). The

corresponding incidence curves are shown by broken lines and case numbers at each RR data point are shown below the figure. The age-RR for 2 affected brothers decreased linearly from RR of 2.8 to RR 1.8. The RR for 3 affected brothers similarly declined, with two modest upward bends, from 3.3 to 2.2. The high RR for 4 brothers in age group 45-49 (N=4) decreased rapidly and peaked again at age 60-64 years (RR 4, N=37) extending to 65-69 years (N=26). For 5+ affected brothers RR reached a peak of RR=7 at age 60-64 years (N=12).

Likely contribution of known predisposition genes

In order to suggest origins for the discrete peaks between ages 50 and 70 years in **Fig. 2** we consulted **Supplementary Table 1** which listed the median penetrance ages for *BRCA1* and *BRCA2* at 66 and 71 years. Those for *MSH2* and *MLH1* were 65 and 70 years. We thus searched for Swedish PC families presenting additionally with familial breast cancer (BC, for *BRCA* genes) or with familial colorectal cancer (CRC, for mismatch repair genes).

Age-RR curves for the PC/BC families are shown in **Fig. 3** when three brothers were affected. The blue curve depicts age-RR when female family members had no BC before age 60 years; red curve depicts families with one and green curve families with two BCs diagnosed before age 60 years, showing a solid peak with an RR of over 5 (N=8) at age 65-69 years. This is the preferential range for age of onset in PC for *BRCA2* and *BRCA1* gene mutations. However, as the case numbers were limited we relaxed the condition for PC to include only two affected brothers **Supplementary Fig. 1**. The green curve families with additionally two BC diagnosed before age 60 years also show a peak (N=22) at age 65-69 years.

Similar data for familial PC are shown in **Fig. 4** when there were family members diagnosed with CRC before age 60 years. Because of low case numbers, only PC families of affected brother pairs could be presented. In **Fig. 4** in families with two CRCs a sharp peak of RR over 3.0 (N=6) was recognized at age 65-69 years. This is the preferential range for age of onset in PC for mismatch repair gene mutations (**Supplementary Table 1**) but as the case numbers were few we reanalyzed the data with only one family member diagnosed with CRC before age 60 years (**Supplementary Fig. 2**). A broad increase in age-RRs covered age groups 65-69 to 80-84 years with most cases at age 65-69 years (N=157).

DISCUSSION

The present study highlights three novel aspects of familial PC. Firstly, we showed distinct risks for full brothers and half-brothers which varied by the time interval between diagnosis of the two brothers. For full brothers the highest SIR of 3.4 followed immediately (within the same year) the diagnosis of the first brother. For maternal half-brothers the peak SIR of 2.7 was reached at 2-3 years and for paternal half-brothers a modest peak of 1.6 was noted at 7-10 years. The second novel result was the demonstration of vastly increasing risk and different age-RR relationships

between families with increasing numbers of affected brothers, most likely signaling variation in genetic background. Age-RR curves in such families pinpointed age-groups of highest risk. The third novelty was the demonstration of the limits for large family studies on PCs to pinpoint discrete genes. We discuss the implications of these findings below.

Half-brothers share 25% of their genes compared to 50% sharing for full-brothers, and environmental sharing is expected to be much higher for maternal than paternal half-brothers because of maternal custody (see Introduction). Theoretically, the difference in cancer risk between maternal and paternal half-brothers would indicate contribution of environmental sharing. However, medical intervention (if maternal half-brothers are more likely to seek medical contact than paternal half-brothers) may distort the theory as was quite pervasively shown in **Fig. 1**. The peak risk was reached fastest for full brothers (within the first year), then for maternal half-brothers (2-3 years) and latest for paternal half-brothers (7-10 years). The median diagnostic time difference between brothers was largest for paternal half-brothers (74 months), deviating from the others (58 and 55 years, respectively), which may be related to sparse contacts between paternal half-brothers. We suggested that the most objective assessment (with least detection bias) of sibling risks would be the period 7+ years after diagnosis of the first brother; the SIRs were 2.06 for full brothers, 1.66 for maternal and 1.41 for paternal half-brothers. Case numbers for half-brothers were few but their risks were significantly increased over SIR 1. The combined risk for half-brothers (1.54, extra risk $1.54-1.00=0.54$) was exactly 50% of that for full brothers (2.06, extra risk 1.06). However, the small difference between maternal and paternal half-brothers (1.66 vs. 1.41) suggests some environmental contribution to the risk of PC.

Cancers with a hereditary component tend to show many affected individuals and thus high familial risk. Here for full-brothers familial risk increased from 2.23 (two brothers with PC) to 3.59, 5.09, 6.94 and 21.33 (up to 6 brothers). Hereditary cancer is often diagnosed at a relatively early age compared to sporadic or life-style related cancers (31). The basis for this is the multi-stage model of carcinogenesis whereby in hereditary cancer one or more genes are constitutionally mutated and thus bypassed already at birth leading to earlier onset of cancer (32). Many familial cancers are also of relatively early onset but there are others with environmental contribution that appear at an advanced age (33). The age-RR curves may transmit information about the underlying genes but the odds of detecting clear peaks of predisposition genes may not be high in view of the literature review which stated that combined known pathogenic germline variants account for no more than 7% of familial PC (7). With the modest familial risk of two brothers we observed an almost linear declining RR-curve (**Fig. 2**), resembling the age-dependent declining risk by PRS of low-risk genes for which rare predisposing genes could contribute (14). At higher number of affected brothers some discrete peaks appeared: with 4 brothers a broad peak with many patients emerged at age 60-69 years which for 5+ affected brothers narrowed to age of 60-64 y reaching an RR of 7. Among the known genes predisposing to PC at a preferential age range of 60-64 years include *ATM*, *CHEK2*, *HOXB13* and *BRCA1* (including also Swedish PC patients, **Supplementary Table 1**). The preferential age for *MSH2*, *MLH1* and

BRCA2 is on the higher side of that age range. However, a note of caution relating to the high risk of PC for the subsequent brothers after first brother's diagnosis is that some detection bias may be present as pointed out in relation to **Table 1**.

We attempted also more specific genetic assignments by incorporating BC patients diagnosed before age 60 years into PC families and showed a discrete peak at age 65-69 years in line with predisposition caused by *BRCA1* and *BRCA2* (**Fig. 3**). Similar data for familial PC incorporating family members diagnosed with CRC before age 60 years defined an excess RR at age 65-74 years (**Fig. 4**), the range known for mismatch repair gene mutations in PC patients (**Supplementary Table 1**). The sizes of the observed peaks were small which should be considered against the background that the prevalence of any known predisposition genes for PC is much less than 2%, (4, 8, 9). Thus, the prerequisite for seeing any discrete peaks would be a strong enrichment of familial cases which we achieved here.

The basic limitation in this kind of study is the small numbers of familial cases in a North European country of 10 million people. However, during and after the Second World War a large number (1.8 million) of immigrants arrived to Sweden, initially from Europa but later also from other continents (34). In non-European immigrants PC incidence was 0.45 and survival 0.6 compared to the Swedish level; incidence and survival in European immigrants was closer to the Swedish levels (35). Comparison of familial risks for PC in Sweden to those in Iceland or Utah shows large similarities (36, 37).

In conclusion, this largest family study on PC yet conducted suggested that, in addition to the main genetic component, a minor environmental component, revealed in analysis of half-brother, may contribute to the familial risk of PC. Familial risk increased step-wise by the number of affected brothers reaching a clinically alarming SIR of 21.33 (6 brothers in a total of 53 families). Age-RR analysis of two-brother families revealed a broad age distribution of risk, probably contributed by a combination of low-risk polygenes combined with environmental factors. When 4 or more brothers were affected, a discrete high-risk age range covered years 60-69 which is the preferential age range of the known predisposition genes for PC. The results illustrate a 'low risk-high risk' heterogeneity of familial risk for PC which should be considered in future etiological studies. There are no generally accepted screening methods for PC, and The European Association of Urology recommends risk adapted strategies for well-informed men interested in a tailored approach for finding PC (38). Certainly, positive family history among FDR is a risk factor but the present study lacking paternal data and information of second-degree relatives is limited for detailed clinical risk prediction. Unfortunately, many ongoing PC PSA-based screening trials do not consider the readily available family history. The present results emphasize the need to take family histories for newly diagnosed PC cases and referral to genetic counseling should be considered when two or more FDRs have been diagnosed with PC.

FIGURE LEGENDS

Fig. 1. Familial risks (SIRs and 95%CI) for PC for the second brother since diagnosis of the first brother at time 0, considering full brothers and maternal and paternal half-brothers.

Fig. 2. Age-specific incidence (left y-axis, dashed lines) and rate ratio (RR, right y-axis, solid lines) for the first diagnosed PC depending on the number of affected brothers in the family. The color code shows the number of affected brothers. The bottom table shows the case numbers in each data point.

Fig. 3. Age-specific incidence (left y-axis, dashed lines) and rate ratio (RR, right y-axis, solid lines) for PC when three brothers were diagnosed with PC regardless of cancers in FDR (blue lines); additionally, one FDR was diagnosed with breast cancer before age 60 years (red lines) or two FDRs were diagnosed with breast cancer before age 60 years (green lines).

Fig. 4. Age-specific incidence (left y-axis, dashed lines) and rate ratio (RR, right y-axis, solid lines) for PC when three brothers were diagnosed with PC (blue lines) and additionally two FDRs were diagnosed with colorectal cancer before age 60 years (red lines).

LEGENDS FOR SUPPLEMENTARY FIGURES

Supplementary Fig. 1. Age-specific incidence (left y-axis, dashed lines) and rate ratio (RR, right y-axis, solid lines) for PC when two brothers were diagnosed with PC regardless of cancers in first-degree relatives (FDRs) (blue lines); additionally one FDR was diagnosed with breast cancer before age 60 years (red lines); additionally two FDRs were diagnosed with breast cancer before age 60 years (green lines).

Supplementary Fig. 2. Age-specific incidence (left y-axis, dashed lines) and rate ratio (RR, right y-axis, solid lines) for PC when (A) two brothers were diagnosed with PC regardless of cancers in FDR (blue lines); additionally one FDR was diagnosed with colorectal cancer before age 60 years (red lines).

ADDITIONAL INFORMATION

Data availability

Anyone wishing to use these data should contact the National Board of Health and Welfare, Stockholm.

Ethics

The study was approved by the Regional Ethical Review Board in Lund University, February 6, 2013 (Reference 2012/795 and subsequent amendments). Informed consent is by law not needed for use of national register data. The study was conducted in accordance with Declaration of Helsinki.

Author contributions

Design: KH, OH

Acquisition of data: KS, JS.

Statistical analysis and interpretation: FZ, KH, AF, AH

Manuscript writing: KH and all other authors.

Approval of the final text: All authors

Conflict of interest

A.H. is shareholder in Circio Holdings ASA. A.H. is employee and shareholder in TILT Biotherapeutics Ltd. Other authors declared no conflict of interest.

Funding

Supported by the SALVAGE project (OP JAK; reg. no. CZ.02.01.01/00/22_008/0004644) - co-financed by the European Union and the state budget of the Czech Republic, Jane and Aatos Erkkö Foundation, Sigrid Juselius Foundation, Finnish Cancer Organizations, University of Helsinki, Helsinki University Central Hospital, Novo Nordisk Foundation, Päivikki and Sakari Sohlberg Foundation.

Consent for publication

Own data were used.

References

1. Rahman N. Realizing the promise of cancer predisposition genes. *Nature*. 2014;505:302-8.
2. Lynch H, Fusaro R, Lynch J. Hereditary cancer in adults. *Cancer Detect Prev*. 1995;19:219-33.
3. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. *N Engl J Med*. 2003;348:919-32.
4. Hemminki K, Kiemeny LA, Morgans AK, Ranniko A, Pichler R, Hemminki O, et al. Hereditary and Familial Traits in Urological Cancers and Their Underlying Genes. *Eur Urol Open Sci*. 2024;69:13-20.
5. Marino F, Totaro A, Gandi C, Bientinesi R, Moretto S, Gavi F, et al. Germline mutations in prostate cancer: a systematic review of the evidence for personalized medicine. *Prostate cancer and prostatic diseases*. 2023;26(4):655-64.

6. Xu J, Lu J, Gielzak M, Lilly Zheng S, Lu L, Wei J, et al. Germline Testing for Prostate Cancer Patients: Evidence-Based Evaluation of Genes Recommended by NCCN Guidelines. *Prostate*. 2025;85(12):1087-95.
7. Finch A, Clark R, Vesprini D, Lorentz J, Kim RH, Thain E, et al. An appraisal of genetic testing for prostate cancer susceptibility. *NPJ Precis Oncol*. 2022;6(1):43.
8. Rantapero T, Wahlfors T, Kähler A, Hultman C, Lindberg J, Tammela TL, et al. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. *Genes*. 2020;11(3).
9. Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Pelttari LM, Kilpivaara O, et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2013;22(3):452-60.
10. Wokolorczyk D, Kluźniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, et al. PALB2 mutations and prostate cancer risk and survival. *Br J Cancer*. 2021;125(4):569-75.
11. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). *Hum Genet*. 2013;132(1):5-14.
12. Sampson JN, Wheeler WA, Yeager M, Panagiotou O, Wang Z, Berndt SI, et al. Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. *J Natl Cancer Inst*. 2015;107(12):djv279.
13. Darst BF, Sheng X, Eeles RA, Kote-Jarai Z, Conti DV, Haiman CA. Combined Effect of a Polygenic Risk Score and Rare Genetic Variants on Prostate Cancer Risk. *Eur Urol*. 2021;80(2):134-8.
14. Schaid DJ, Sinnwell JP, Batzler A, McDonnell SK. Polygenic risk for prostate cancer: Decreasing relative risk with age but little impact on absolute risk. *Am J Hum Genet*. 2022;109(5):900-8.
15. Ji C, Ge W, Zhu C, Shen F, Yu Y, Pang G, et al. Family history and genetic risk score combined to guide cancer risk stratification: A prospective cohort study. *Int J Cancer*. 2025;156(3):505-17.
16. Zhang Z, Zhang Y, Stopsack KH, Kibel AS, Giovannucci EL, Penney KL, et al. Identifying Patients at Risk of Early Lethal Prostate Cancer by Integrating Family History, Polygenic Risk Score, Rare Variants in DNA Repair Genes, and Lifestyle Factors. *European urology oncology*. 2025.
17. Weires M, Bermejo JL, Sundquist J, Hemminki K. Clustering of concordant and discordant cancer types in Swedish couples is rare. *Eur J Cancer*. 2011;47:98-106.
18. Hemminki K, Zitricky F, Sundquist K, Sundquist J, Försti A, Hemminki A. Lung cancer risk between maternal and paternal half-siblings points to main environmental causation and targets for prevention. *Lung Cancer*. 2025;202:108500.
19. Hemminki K, Ji J, Brandt A, Mousavi SM, Sundquist J. The Swedish Family-Cancer Database 2009: Prospects for histology-specific and immigrant studies. *Int J Cancer*. 2010;126:2259-67.
20. Fransson E, Hjern A, Bergström M. What Can We Say Regarding Shared Parenting Arrangements for Swedish Children? *Journal of Divorce & Remarriage*. 2018;59:349-58.
21. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age at diagnosis and age at death in familial prostate cancer. *Oncologist*. 2009;14:1209-17.
22. Brandt A, Bermejo JL, Sundquist J, Hemminki K. Age-Specific Risk of Incident Prostate Cancer and Risk of Death from Prostate Cancer Defined by the Number of Affected Family Members. *Eur Urol*. 2010;58:275-80.

23. Brandt A, Sundquist J, Hemminki K. Risk for incident and fatal prostate cancer in men with a family history of any incident and fatal cancer. *Ann Oncol.* 2012(23):i251-6.
24. Xu X, Kharazmi E, Tian Y, Mukama T, Sundquist K, Sundquist J, et al. Risk of prostate cancer in relatives of prostate cancer patients in Sweden: A nationwide cohort study. *PLoS Med.* 2021;18(6):e1003616.
25. Hemminki K, Rawal R, Bermejo JL. Prostate cancer screening, changing age-specific incidence trends and implications on familial risk. *Int J Cancer.* 2005;113:312-5.
26. Hemminki K, Sundquist K, Sundquist J, Försti A, Hemminki A, Li X. Familial Risks and Proportions Describing Population Landscape of Familial Cancer. *Cancers.* 2021;13(17).
27. Hemminki K, Försti A, Hemminki O, Scott RJ, Hemminki A. Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers. *Hereditary cancer in clinical practice.* 2025;23(1):7.
28. Vickers A, O'Brien F, Montorsi F, Galvin D, Bratt O, Carlsson S, et al. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. *Bmj.* 2023;381:e071082.
29. Lorenzo Bermejo J, Hemminki K. Familial risk of cancer shortly after diagnosis of the first familial tumor. *J Natl Cancer Inst.* 2005;97:1575-9.
30. Bratt O, Garmo H, Adolfsson J, Bill-Axelsson A, Holmberg L, Lambe M, et al. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates. *J Natl Cancer Inst.* 2010;102:1336-43.
31. Garber JE, Offit K. Hereditary cancer predisposition syndromes. *J Clin Oncol.* 2005;23:276-92.
32. Armitage P, Doll R. The age distribution of cancer and a multi-stage theory of carcinogenesis. *Br J Cancer.* 1954;8:1-12.
33. Kharazmi E, Fallah M, Sundquist K, Hemminki K. Familial risk of early and late onset cancer: nationwide prospective cohort study. *BMJ.* 2012;345:e8076.
34. Hemminki K, Försti A, Khyatti M, Anwar WA, Mousavi M. Cancer in immigrants as a pointer to the causes of cancer. *European journal of public health.* 2014;24 Suppl 1:64-71.
35. Hemminki K, Ankerst DP, Sundquist J, Mousavi SM. Prostate cancer incidence and survival in immigrants to Sweden. *World J Urol.* 2013;31(6):1483-8.
36. Amundadottir LT, Thorvaldsson S, Gudbjartsson DF, Sulem P, Kristjansson K, Arnason S, et al. Cancer as a Complex Phenotype: Pattern of Cancer Distribution within and beyond the Nuclear Family. *PLoS Med.* 2004;1:e65.
37. Teerlink CC, Albright FS, Lins L, Cannon-Albright LA. A comprehensive survey of cancer risks in extended families. *Genet Med.* 2012;14(1):107-14.
38. Van Poppel H, Roobol MJ, Chapple CR, Catto JWF, N'Dow J, Sønksen J, et al. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021. *Eur Urol.* 2021;80(6):703-11.

Table 1. Relative risk (SIR) for PC based on brothers diagnosed with PC (full brothers, maternal and paternal half-brothers) with cancer in any brothers or in first brother only. N=number of observed familial PC cases in respective family constellations (see methods). First brother is the first one diagnosed in a brotherhood.

Brothers with PC			Risk to any brother		Risk to first brother	
Full brother	Maternal HB	Paternal HB	N familial	SIR [95% CI]	N familial	SIR [95% CI]
0	0	2	339	1.34 [1.20-1.49]	178	1.39 [1.20-1.61]
0	2	0	382	1.92 [1.73-2.12]	188	1.87 [1.61-2.16]
0	2	2	16	2.75 [1.57-4.46]	7	2.74 [1.10-5.66]
2	0	0	16290	2.23 [2.19-2.26]	8139	2.14 [2.09-2.19]
3	0	0	2429	3.59 [3.45-3.74]	806	3.34 [3.12-3.58]
4	0	0	398	5.09 [4.60-5.62]	98	4.25 [3.45-5.18]
4	0	0	84	6.94 [5.53-8.59]	16	5.40 [3.09-8.77]
6	0	0	53	21.33 [15.98-27.9]	9	16.78 [7.68-31.87]

Fig. 1






Fig. 2




Cases in family	N total	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
2 Brothers	8176	.	6	69	436	1353	2317	2327	1197	400	66	5
3 Brothers	813	.	.	8	65	178	246	218	78	18	2	.
4 Brothers	100	.	.	4	7	19	37	26	5	2	.	.
5+ Brothers	24	.	.	.	3	7	12	2	.	.	.	.
Reference	79693	4	28	266	2139	7666	16798	22729	17195	9442	3017	409

Fig. 3



Family history	N total	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
3 Brothers PC + NO BC	2004	.	.	9	80	290	491	535	388	163	47	1
3 Brothers PC + 1 BC < 60	185	.	.	1	6	20	43	56	42	10	7	.
3 Brothers PC + 2 BC < 60	19	.	.	.	.	2	3	8	2	3	1	.
Reference	80740	5	31	300	2400	8244	17431	22854	16953	9237	2901	384

Fig. 4



Family history	N total	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
2 Brothers PC + NO CRC	14852	.	7	75	514	1749	3472	4250	2879	1470	395	41
2 Brothers PC + 2 CRC<60	13	.	.	.	1	1	2	6	2	1	.	.
Reference	82611	5	34	304	2451	8557	17888	23398	17285	9377	2916	396

Supplementary Table 1. Penetrance age for predisposition genes in prostate cancer (PC), breast cancer (BC), ovarian cancer (OvCa) and colorectal cancer (CRC).

Gene	Prevalence in PC (ref. 5)	Median age in PC	Median age in BC	Median age in OvCa	Median age in CRC	Reference for median age of BC, OvCa, CRC
BRCA2	3.80%	71 y	40 y (US); 42y (Sweden)	58 y		(1-3)
ATM	2.70%	60 y	x			(1)
CHEK2	2.50%	63 y (1100delC) 64 y (I157T)	x			(1)
BRCA1	0.80%	66 y	30s y (US); 50 y (Sweden)	53 y		(1-3)
PALB2	0.40%		x			(1)
MSH2	1.20%	65 y			56 y	(4)
MLH1	0.10%	70 y			50 y	(4)
MSH6	0.80%				62 y	(4)
PMS2	0.60%					
HOXB13	1.20%	62-63 y (G84E)				

According to Pritzlaff the prevalence of common pathogenic variants among PC predisposition genes decreased in order *BRCA2* 3.8%, *ATM* 2.7%, *CHEK2* 2.5%, *HOXB13* 1.2%, *MSH2* 1.2%, *BRCA1* 0.8%, *MSH6* 0.8%, *PMS2* 0.6% (**Supplementary Table 1**) (5). The results were reported by a Californian testing laboratory and several patients had diverse earlier cancers and/or family history of some cancers but the results are in line with other reports (6, 7). In PC, the median diagnostic age for *BRCA1* mutation carriers has been 66 years and that for *BRCA2* 71 years (8). For *ATM* mutation carriers median diagnostic age has been earlier, at 60 years (9). In hereditary PC, *CHEK2* 1100delC mutation carriers were found at a median age of 63 years compared to I157T carriers at age of 64 years (10). However in non-familial PC the diagnostic age has been 69 years (11). Enrichment of *ATM*, *CHEK2* and *PALB2* mutations have been reported in lethal PC (12, 13). According to the Prospective Lynch Syndrome Database cumulative incidence of PC by age 75 years was highest in *MSH2* mutation carriers (24%) and *MLH1* carriers (14%) with a median age of onset at 65 and 70 years, respectively (4). Mutations in *HOXB13* show extensive geographic variation with high frequency of risk alleles in Finland and Scandinavia (from 1 to 3% of PCs) (14-16). The median age of onset for the G84E carriers has been 62-63 years (14). However, lower ages were reported in US hereditary PC but also higher ages have been reported from UK (17, 18). The G84E variant is not associated with colorectal cancer while it may have a weak association with breast cancer (19).


It is noteworthy that the median diagnostic age for important cancer predisposition genes in PC differs extensively from that of other cancers (**Supplementary Table 1**). In US breast cancer patients, the median age of onset of *BRCA1* related mutations is in the 30s and that for *BRCA2* at around 40 years; however, early diagnostic age was not a feature of genes *ATM*, *CHEK2*, or *PALB2* (1). In Swedish breast cancer patients, the median onset is later, about 42 years for *BRCA1* and 50 years for *BRCA2* (3). In ovarian cancer the median age of diagnosis

for *BRCA1* and *BRCA2* is at ages 53 and 58 years (2). In colorectal cancer mismatch repair gene mutations appeared far earlier than in PC, median ages being around 50 years for *MLH1*, 56 years for *MSH2* and 62 years for *MSH6* (4). For endometrial cancer the median ages were close to colorectal cancer, but for *MSH2* and *MSH6* lower, about 55 years (2).

1. Daly MB, Rosenthal E, Cummings S, Bernhisel R, Kidd J, Hughes E, et al. The association between age at breast cancer diagnosis and prevalence of pathogenic variants. *Breast Cancer Res Treat.* 2023;199(3):617-26.
2. Marchetti C, Ataseven B, Cassani C, Sassu CM, Congedo L, D'Indinosante M, et al. Ovarian cancer onset across different BRCA mutation types: a view to a more tailored approach for BRCA mutated patients. *Int J Gynecol Cancer.* 2023;33(2):257-62.
3. Winter C, Nilsson MP, Olsson E, George AM, Chen Y, Kvist A, et al. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic. *Ann Oncol.* 2016;27(8):1532-8.
4. Dominguez-Valentin M, Sampson JR, Seppälä TT, Ten Broeke SW, Plazzer JP, Nakken S, et al. Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database. *Genet Med.* 2020;22(1):15-25.
5. Pritzlaff M, Tian Y, Reineke P, Stuenkel AJ, Allen K, Gutierrez S, et al. Diagnosing hereditary cancer predisposition in men with prostate cancer. *Genet Med.* 2020;22(9):1517-23.
6. Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, et al. Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. *JCO Precis Oncol.* 2019;3.
7. Paulo P, Cardoso M, Brandão A, Pinto P, Falconi A, Pinheiro M, et al. Genetic landscape of homologous recombination repair genes in early-onset/familial prostate cancer patients. *Genes Chromosomes Cancer.* 2023;62(12):710-20.
8. Nyberg T, Frost D, Barrowdale D, Evans DG, Bancroft E, Adlard J, et al. Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. *Eur Urol.* 2020;77(1):24-35.
9. Karlsson Q, Brook MN, Dadaev T, Wakerell S, Saunders EJ, Muir K, et al. Rare Germline Variants in ATM Predispose to Prostate Cancer: A PRACTICAL Consortium Study. *European urology oncology.* 2021;4(4):570-9.
10. Seppälä EH, Ikonen T, Mononen N, Autio V, Rökman A, Matikainen MP, et al. CHEK2 variants associate with hereditary prostate cancer. *Br J Cancer.* 2003;89(10):1966-70.
11. Wang Y, Dai B, Ye D. CHEK2 mutation and risk of prostate cancer: a systematic review and meta-analysis. *Int J Clin Exp Med.* 2015;8(9):15708-15.
12. Rantapero T, Wahlfors T, Kähler A, Hultman C, Lindberg J, Tammela TL, et al. Inherited DNA Repair Gene Mutations in Men with Lethal Prostate Cancer. *Genes.* 2020;11(3).
13. Wokolorczyk D, Kluźniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, et al. PALB2 mutations and prostate cancer risk and survival. *Br J Cancer.* 2021;125(4):569-75.
14. Karlsson R, Aly M, Clements M, Zheng L, Adolfsson J, Xu J, et al. A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. *Eur Urol.* 2014;65(1):169-76.
15. Storebjerg TM, Høyer S, Kirkegaard P, Bro F, Ørntoft TF, Borre M, et al. Prevalence of the HOXB13 G84E mutation in Danish men undergoing radical prostatectomy and its correlations with prostate cancer risk and aggressiveness. *BJU Int.* 2016;118(4):646-53.


16. Chen H, Ewing CM, Zheng S, Grindedal EM, Cooney KA, Wiley K, et al. Genetic factors influencing prostate cancer risk in Norwegian men. *Prostate*. 2018;78(3):186-92.
17. Nyberg T, Govindasami K, Leslie G, Dadaev T, Bancroft E, Ni Raghallaigh H, et al. Homeobox B13 G84E Mutation and Prostate Cancer Risk. *Eur Urol*. 2019;75(5):834-45.
18. Ewing CM, Ray AM, Lange EM, Zuhlke KA, Robbins CM, Tembe WD, et al. Germline mutations in HOXB13 and prostate-cancer risk. *N Engl J Med*. 2012;366(2):141-9.
19. Laitinen VH, Wahlfors T, Saaristo L, Rantapero T, Peltari LM, Kilpivaara O, et al. HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. *Cancer Epidemiol Biomarkers Prev*. 2013;22(3):452-60.

Suppl. Fig. 1



Family history	N total	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
2 Brothers PC + NO BC	13719	.	5	63	444	1619	3127	4019	2656	1381	366	39
2 Brothers PC + 1 BC < 60	1034	.	1	5	39	114	249	272	217	103	32	2
2 Brothers PC + 2 BC < 60	71	.	.	.	4	9	15	22	11	7	3	.
Reference	80740	5	31	300	2400	8244	17431	22854	16953	9237	2901	384

Suppl. Fig. 2



Family history	N total	35-39	40-44	45-49	50-54	55-59	60-64	65-69	70-74	75-79	80-84	85-89
2 Brothers PC + NO CRC	14852	.	7	75	514	1749	3472	4250	2879	1470	395	41
2 Brothers PC + 1 CRC<60	504	.	.	3	10	62	98	157	101	56	16	1
Reference	82611	5	34	304	2451	8557	17888	23398	17285	9377	2916	396